[HTML][HTML] Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass …
M Nishimura, M Hayashi, Y Mizutani, K Takenaka… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Background The development of skin rashes is the most common adverse event observed in
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry …
M Nishimura, M Hayashi, Y Mizutani, K Takenaka… - Oncotarget, 2018 - europepmc.org
Background The development of skin rashes is the most common adverse event observed in
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry …
M Nishimura, M Hayashi, Y Mizutani, K Takenaka… - Oncotarget, 2018 - cir.nii.ac.jp
Background: The development of skin rashes is the most common adverse event observed
in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors …
in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors …
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry …
M Nishimura, M Hayashi, Y Mizutani… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Background The development of skin rashes is the most common adverse event observed in
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …
[HTML][HTML] Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass …
M Nishimura, M Hayashi, Y Mizutani, K Takenaka… - Oncotarget, 2018 - oncotarget.com
Abstract Meiko Nishimura 1,*, Mitsuhiro Hayashi 2, 3,*, Yu Mizutani 1, Kei Takenaka 1,
Yoshinori Imamura 1, Naoko Chayahara 1, 4, Masanori Toyoda 1, Naomi Kiyota 1, Toru …
Yoshinori Imamura 1, Naoko Chayahara 1, 4, Masanori Toyoda 1, Naomi Kiyota 1, Toru …
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry …
M Nishimura, M Hayashi, Y Mizutani, K Takenaka… - da.lib.kobe-u.ac.jp
Background: The development of skin rashes is the most common adverse event observed
in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors …
in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors …
[引用][C] Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry …
M Nishimura, M Hayashi, Y Mizutani, K Takenaka… - Oncotarget, 2018 - cir.nii.ac.jp
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized
by matrix assisted laser desorption/ionization mass spectrometry imaging | CiNii Research …
by matrix assisted laser desorption/ionization mass spectrometry imaging | CiNii Research …
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry …
M Nishimura, M Hayashi, Y Mizutani, K Takenaka… - Oncotarget, 2018 - oncotarget.com
Abstract Meiko Nishimura 1,*, Mitsuhiro Hayashi 2, 3,*, Yu Mizutani 1, Kei Takenaka 1,
Yoshinori Imamura 1, Naoko Chayahara 1, 4, Masanori Toyoda 1, Naomi Kiyota 1, Toru …
Yoshinori Imamura 1, Naoko Chayahara 1, 4, Masanori Toyoda 1, Naomi Kiyota 1, Toru …
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry …
M Nishimura, M Hayashi, Y Mizutani, K Takenaka… - Oncotarget, 2018 - europepmc.org
Background The development of skin rashes is the most common adverse event observed in
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …